People with ADHD were three times more likely to use cannabis, and hyperactive types started youngest

Cannabis use prevalence was 14.3% in adults with ADHD versus 4.3% in those without, with the hyperactive subtype initiating use at age 13.8 compared to 16.3 for the inattentive subtype.

Brandt, Ariel et al.·The Journal of nervous and mental disease·2018·Moderate EvidenceCross-Sectional
RTHC-01602Cross SectionalModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Using data from the National Epidemiologic Survey on Alcohol and Related Conditions, researchers examined cannabis use patterns among adults with and without ADHD. The prevalence of cannabis use was more than three times higher in people with ADHD (14.3%) compared to those without (4.3%).

Among ADHD patients who used cannabis, those with the hyperactive subtype initiated use significantly earlier, at an average age of 13.8 years, compared to 16.3 years for the inattentive subtype. This 2.5-year gap in initiation age is clinically meaningful given the vulnerability of the developing brain during early adolescence.

Cannabis-using ADHD patients also had notably higher rates of psychiatric comorbidity. Having any psychiatric disorder was 2.8 times more likely, and lifetime personality disorders were 4 times more likely in ADHD patients who used cannabis compared to those who did not.

Key Numbers

Cannabis use prevalence: 14.3% with ADHD vs 4.3% without. Hyperactive subtype initiation age: 13.8 years. Inattentive subtype initiation age: 16.3 years (p = 0.0017). Any psychiatric disorder: AOR = 2.8 (95% CI 1.08-6.41). Lifetime personality disorder: AOR = 4.04 (95% CI 1.84-8.84).

How They Did This

Data were from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (2004-2005). Psychiatric disorders were assessed using the AUDADIS structured interview. Multivariate logistic regression models adjusted for sociodemographics, psychiatric disorders, and substance use disorders.

Why This Research Matters

ADHD is one of the most common neurodevelopmental disorders, and understanding its relationship with cannabis use has practical implications. The finding that hyperactive individuals start using cannabis nearly 2.5 years earlier than inattentive types suggests that impulsivity and hyperactivity drive earlier substance use initiation, creating a larger window of developmental vulnerability.

The Bigger Picture

This study sits at the intersection of two major public health topics: ADHD management and cannabis use. As some people with ADHD turn to cannabis for self-medication (particularly for restlessness and sleep), understanding the risks and patterns of this co-occurrence becomes increasingly important, especially given the high rates of psychiatric comorbidity observed.

What This Study Doesn't Tell Us

The cross-sectional design cannot determine whether ADHD drives cannabis use or whether both share common risk factors. The data are from 2004-2005 and may not reflect current patterns. Self-reported ADHD diagnosis and cannabis use may be subject to recall bias. The study cannot assess whether cannabis use represented self-medication for ADHD symptoms.

Questions This Raises

  • ?Does treating ADHD effectively reduce the risk of cannabis use initiation?
  • ?Are people with ADHD self-medicating with cannabis, and if so, does it help or harm their symptoms?
  • ?Should ADHD treatment guidelines specifically address cannabis use prevention?

Trust & Context

Key Stat:
Cannabis use 3x more common in ADHD; hyperactive type started 2.5 years earlier
Evidence Grade:
This is a large national survey with appropriate statistical controls, providing moderate evidence of associations between ADHD and cannabis use patterns.
Study Age:
Published in 2018 with data from 2004-2005. Cannabis accessibility has changed significantly since.
Original Title:
Clinical Correlates of Cannabis Use Among Individuals With Attention Deficit Hyperactivity Disorder.
Published In:
The Journal of nervous and mental disease, 206(9), 726-732 (2018)
Database ID:
RTHC-01602

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Is cannabis more common in people with ADHD?

Yes. This study found that 14.3% of adults with ADHD used cannabis compared to 4.3% of those without, a threefold difference. ADHD patients who used cannabis also had much higher rates of other psychiatric conditions.

Does the type of ADHD matter?

Yes. People with the hyperactive subtype started using cannabis at an average age of 13.8, nearly 2.5 years earlier than those with the inattentive subtype (16.3 years). Earlier initiation during adolescent brain development is considered a greater risk factor.

Read More on RethinkTHC

Cite This Study

RTHC-01602·https://rethinkthc.com/research/RTHC-01602

APA

Brandt, Ariel; Rehm, Jürgen; Lev-Ran, Shaul. (2018). Clinical Correlates of Cannabis Use Among Individuals With Attention Deficit Hyperactivity Disorder.. The Journal of nervous and mental disease, 206(9), 726-732. https://doi.org/10.1097/NMD.0000000000000877

MLA

Brandt, Ariel, et al. "Clinical Correlates of Cannabis Use Among Individuals With Attention Deficit Hyperactivity Disorder.." The Journal of nervous and mental disease, 2018. https://doi.org/10.1097/NMD.0000000000000877

RethinkTHC

RethinkTHC Research Database. "Clinical Correlates of Cannabis Use Among Individuals With A..." RTHC-01602. Retrieved from https://rethinkthc.com/research/brandt-2018-clinical-correlates-of-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.